Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URCC 16070: Olanzapine vs Prochlorperazine for Refractory CINV in Breast Cancer
NCT03367572Phase 3Completed
- Sponsor
- University of Rochester Cancer Center NCORP Research Base
- Start
- Apr 2018
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olanzapine, prochlorperazine in chemotherapy-induced nausea and vomiting (CINV), sponsored by University of Rochester Cancer Center NCORP Research Base. Started Apr 2018; status: completed.
02
Drugs
olanzapineprochlorperazine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03367572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03367572.